资金流向方面，主力资金净流出1964.05万元，特大单买入0.00元，占比0.00%，卖出1785.97万元，占比 14.56%；大单买入2001.59万元，占比16.32%，卖出2179.67万元，占比17.77%。 天康生物今年以来股价涨12.32%，近5个交易日跌3.79%，近20日跌5.83%，近60日涨7.24%。 资料显示，天康生物股份有限公司位于新疆维吾尔自治区乌鲁木齐市高新区长春南路528号天康企业大 厦，成立日期2000年12月28日，上市日期2006年12月26日，公司主营业务涉及畜禽用生物疫苗、饲料及 饲用植物蛋白的生产、销售,种猪繁育、生猪养殖、屠宰加工及肉制品销售。主营业务收入构成为：生 猪养殖产业链收入32.20%，饲料收入27.51%，蛋白油脂加工收入16.37%，玉米收入14.75%，兽药收入 5.44%，其他收入3.40%，其他(补充)0.29%，担保费收入0.04%。 天康生物所属申万行业为：农林牧渔-饲料-畜禽饲料。所属概念板块包括：疫苗、宠物经济、动物疫 苗、猪肉概念、融资融券等。 12月1日，天康生物盘中下跌2.07%，截至13:29，报7.11元/股，成交1.23亿 ...

Core Viewpoint - Wante Bio's stock has experienced a significant decline this year, with a 30.39% drop, and the company is facing challenges in revenue and profit margins [1][2]. Financial Performance - For the period from January to September 2025, Wante Bio reported a revenue of 1.498 billion yuan, a year-on-year decrease of 23.09% [2]. - The net profit attributable to the parent company was -173 million yuan, reflecting a year-on-year decrease of 165.04% [2]. Stock Market Activity - As of December 1, Wante Bio's stock price was 49.05 yuan per share, with a market capitalization of 62.054 billion yuan [1]. - The stock has seen a trading volume of 1.06 billion yuan, with a turnover rate of 0.17% [1]. - The stock has experienced a decline of 4.76% over the last five trading days and 11.21% over the last 20 days [1]. Shareholder Information - As of September 30, 2025, the number of shareholders increased to 42,000, a rise of 9.41% [2]. - The average number of circulating shares per shareholder decreased by 8.60% to 30,124 shares [2]. Dividend Distribution - Wante Bio has distributed a total of 1.541 billion yuan in dividends since its A-share listing, with 1.311 billion yuan distributed over the past three years [3]. Institutional Holdings - As of September 30, 2025, Hong Kong Central Clearing Limited was the fifth-largest circulating shareholder, holding 12.8991 million shares, a decrease of 9.8553 million shares from the previous period [3]. - The top ten circulating shareholders included new entrants and exits, indicating changes in institutional interest [3].

Core Viewpoint - The stock price of Wens Foodstuff Group Co., Ltd. has shown fluctuations, with a current price of 17.71 CNY per share, reflecting a year-to-date increase of 10.60% but a recent decline over the past 20 and 60 days [1] Financial Performance - For the period from January to September 2025, Wens achieved a revenue of 75.82 billion CNY, representing a year-on-year growth of 0.53%. However, the net profit attributable to shareholders decreased by 17.98% to 5.26 billion CNY [2] - Cumulative cash dividends since the A-share listing amount to 30.11 billion CNY, with 6.28 billion CNY distributed over the last three years [3] Shareholder Information - As of September 30, 2025, the number of shareholders decreased by 10.94% to 81,100, while the average circulating shares per person increased by 12.11% to 73,543 shares [2] - The top ten circulating shareholders include Hong Kong Central Clearing Limited, which holds 144 million shares, an increase of 5.50 million shares from the previous period [3]

Core Viewpoint - Wante Bio's stock has experienced a significant decline in 2023, with a year-to-date drop of 31.73% and a recent 60-day decline of 17.40% [2] Company Overview - Wante Bio, established on April 24, 1991, and listed on April 29, 2020, is located in Changping District, Beijing. The company specializes in the research, production, and sales of in vitro diagnostic reagents, instruments, and vaccines [2] - The revenue composition of Wante Bio includes: diagnostic reagents (67.06%), vaccines (20.36%), diagnostic instruments (4.98%), agency products (4.97%), other (1.88%), and active raw materials (0.76%) [2] - As of September 30, 2025, Wante Bio had 42,000 shareholders, an increase of 9.41% from the previous period, with an average of 30,124 circulating shares per shareholder, a decrease of 8.60% [2] Financial Performance - For the period from January to September 2025, Wante Bio reported a revenue of 1.498 billion yuan, a year-on-year decrease of 23.09%, and a net profit attributable to shareholders of -173 million yuan, a year-on-year decrease of 165.04% [2] - Since its A-share listing, Wante Bio has distributed a total of 1.541 billion yuan in dividends, with 1.311 billion yuan distributed over the past three years [3] Shareholder Structure - As of September 30, 2025, the top ten circulating shareholders of Wante Bio include Hong Kong Central Clearing Limited, which holds 12.8991 million shares (a decrease of 9.8553 million shares), and Huatai-PB CSI 300 ETF, holding 6.4061 million shares (a decrease of 318,300 shares) [3] - The China National Securities Bio-Medical Index A has entered the top ten circulating shareholders with 4.9609 million shares as a new shareholder, while E Fund CSI 300 Medical ETF has exited the list [3] Market Activity - On November 28, Wante Bio's stock price fell by 2.02%, trading at 48.10 yuan per share, with a total transaction volume of 131 million yuan and a turnover rate of 0.21%. The total market capitalization is 60.852 billion yuan [1] - In terms of capital flow, there was a net outflow of 17.3687 million yuan from main funds, with large orders showing a buy of 23.094 million yuan (17.66%) and a sell of 27.222 million yuan (20.82%) [1]

Market Overview - Major Asia-Pacific stock indices mostly rose, with Japan's Nikkei 225 up 1.85% to 49,559.07 points and South Korea's KOSPI up 2.67% to 3,960.87 points [1] - A-shares showed strength, with the ChiNext Index surging over 3% at one point; however, the Shanghai Composite Index closed down 0.15% at 3,864.18 points [1] Retail Sector Performance - Retail stocks experienced a significant surge, with companies like Kai Chun Co. and Huaren Health hitting the 20% limit up, and Huanle Jia rising over 15% [3][4] - The Ministry of Industry and Information Technology and other departments released a plan to enhance consumer goods supply and demand adaptability, aiming for a noticeable optimization of the supply structure by 2027 [5] AI Industry Activity - AI-related stocks were active, with companies like Changguang Huaxin and Saiwei Electronics seeing gains of 20% and over 16% respectively [7][8] - Alibaba reported a 34% year-on-year increase in cloud revenue for Q2 FY2026, with AI-related product revenue growing for nine consecutive quarters [9] Pharmaceutical Sector Strength - The pharmaceutical sector saw strong performance, particularly in innovative drugs and vaccines, with companies like Yue Wannianqing and Huaren Health reaching the 20% limit up [11][12] - The small nucleic acid drug sector is gaining attention due to recent advancements, indicating a potential golden development period driven by technological breakthroughs and commercial validation [13]

Core Viewpoint - Boda Pharmaceutical's stock has experienced a decline of 5.98% year-to-date, with significant drops over various time frames, indicating potential challenges in the market [1][2]. Financial Performance - For the period from January to September 2025, Boda Pharmaceutical achieved a revenue of 2.717 billion yuan, reflecting a year-on-year growth of 15.90%. However, the net profit attributable to shareholders decreased by 23.86% to 317 million yuan [2]. - Cumulative cash dividends since the company's A-share listing amount to 669 million yuan, with 184 million yuan distributed over the past three years [3]. Stock Market Activity - As of November 26, Boda Pharmaceutical's stock price was 50.52 yuan per share, with a market capitalization of 21.255 billion yuan. The stock saw a net inflow of 4.3816 million yuan from main funds [1]. - The company has seen a decrease in shareholder accounts, with a total of 29,500 shareholders as of September 30, down by 7.99%. The average number of circulating shares per person increased by 8.68% to 14,198 shares [2]. Shareholder Composition - As of September 30, 2025, the top ten circulating shareholders include new entrants such as Xingquan Commercial Model Mixed Fund A and Xingquan Helun Mixed Fund A, while some funds like China Europe Medical Health Mixed Fund A have exited the top ten list [3].

Core Viewpoint - Changchun High-tech's stock has experienced a decline in recent trading sessions, with significant net outflows of capital and a decrease in both revenue and net profit year-on-year [1][2]. Financial Performance - For the period from January to September 2025, Changchun High-tech reported operating revenue of 9.807 billion yuan, a year-on-year decrease of 5.60% [2]. - The net profit attributable to shareholders was 1.165 billion yuan, reflecting a substantial year-on-year decline of 58.23% [2]. Stock Market Activity - On November 21, Changchun High-tech's stock price fell by 2.01%, trading at 99.65 yuan per share, with a total market capitalization of 40.651 billion yuan [1]. - The stock has seen a year-to-date increase of 2.86%, but has declined by 4.69% over the last five trading days and 15.44% over the last 20 days [1]. Shareholder Information - As of September 30, 2025, the number of shareholders decreased by 4.63% to 104,100, while the average number of circulating shares per person increased by 4.85% to 3,840 shares [2]. - The top ten circulating shareholders include significant institutional investors, with Hong Kong Central Clearing Limited being the third-largest shareholder, increasing its holdings by 1.307 million shares [3]. Dividend Distribution - Since its A-share listing, Changchun High-tech has distributed a total of 4.791 billion yuan in dividends, with 3.259 billion yuan distributed over the past three years [3].

Core Points - Boda Pharmaceutical's stock price decreased by 2.08% on November 21, reaching 49.06 CNY per share, with a market capitalization of 20.641 billion CNY [1] - The company has experienced a year-to-date stock price decline of 8.69%, with a 9.68% drop over the last five trading days and a 23.44% decline over the past 60 days [1] - As of September 30, 2025, Boda Pharmaceutical reported a revenue of 2.717 billion CNY, a year-on-year increase of 15.90%, while the net profit attributable to shareholders decreased by 23.86% to 317 million CNY [2] Financial Performance - The company has distributed a total of 669 million CNY in dividends since its A-share listing, with 184 million CNY distributed over the last three years [3] - As of September 30, 2025, the number of shareholders decreased by 7.99% to 29,500, while the average number of circulating shares per person increased by 8.68% to 14,198 shares [2] Shareholder Structure - Among the top ten circulating shareholders, Xingshan Commercial Model Mixed Fund A is the fifth largest with 5.827 million shares, marking a new entry [3] - E Fund's Growth Enterprise Board ETF, ranked sixth, reduced its holdings by 912,300 shares to 5.456 million shares [3] - Xingshan Helun Mixed Fund A is the seventh largest shareholder with 5.402 million shares, also a new entry [3]

11月19日，西藏药业盘中下跌2.00%，截至13:24，报44.55元/股，成交1.05亿元，换手率0.72%，总市值 143.59亿元。 西藏药业所属申万行业为：医药生物-生物制品-其他生物制品。所属概念板块包括：疫苗、创新药、生 物医药、医疗器械、中药等。 截至9月30日，西藏药业股东户数4.54万，较上期增加0.57%；人均流通股7092股，较上期减少0.57%。 2025年1月-9月，西藏药业实现营业收入20.89亿元，同比减少3.96%；归母净利润7.22亿元，同比减少 8.85%。 分红方面，西藏药业A股上市后累计派现22.58亿元。近三年，累计派现15.80亿元。 机构持仓方面，截止2025年9月30日，西藏药业十大流通股东中，香港中央结算有限公司位居第七大流 通股东，持股365.85万股，相比上期增加106.82万股。创新药（159992）位居第九大流通股东，持股 158.17万股，为新进股东。南方中证1000ETF（512100）位居第十大流通股东，持股147.59万股，为新 进股东。华夏行业景气混合A（003567）退出十大流通股东之列。 责任编辑：小浪快报 资金流向方面，主力资金净流出 ...

资料显示，浙江亨通控股股份有限公司位于浙江省湖州市德清县玉屏路地理信息小镇C15幢，成立日期 1999年5月11日，上市日期1999年11月16日，公司主营业务涉及生物农药、兽药、饲料添加剂产品的生 产与销售、热电联供等相关业务。主营业务收入构成为：电解铜箔67.62%，电与蒸汽16.17%，兽药 16.14%，其他业务0.06%。 11月19日，亨通股份盘中下跌2.05%，截至10:08，报4.30元/股，成交6917.87万元，换手率0.53%，总市 值127.90亿元。 资金流向方面，主力资金净流出922.92万元，特大单买入623.93万元，占比9.02%，卖出1031.25万元， 占比14.91%；大单买入1713.06万元，占比24.76%，卖出2228.67万元，占比32.22%。 亨通股份今年以来股价涨68.63%，近5个交易日涨1.18%，近20日跌5.49%，近60日涨35.65%。 今年以来亨通股份已经1次登上龙虎榜，最近一次登上龙虎榜为8月29日，当日龙虎榜净买入4805.76万 元；买入总计1.46亿元 ，占总成交额比22.97%；卖出总计9786.16万元 ，占总成交额比15.40 ...